… With the idea that genetic traits have a role in treatment … a prediction model for long-acting
bronchodilator treatment response, using patient clinical characteristics, and genetic traits, …

… With the idea that genetic traits have a role in treatment … prediction model for long-acting
bronchodilator treatment response, using patient clinical characteristics, as well as genetic traits, …

… as clinical characteristics. Methods: We performed a prospective crossover study, in which
each long-acting bronchodilator was given in a random order to 65 patients with stable COPD …

… , and smoking cessation) or treatments provided to all participants (breath retraining, long-acting
beta-agonist/long-acting muscarinic antagonist use, provision of a written action plan) …

… long-acting bronchodilators). Adherence underpins successful pharmacotherapy of all …
evaluated the treatable traits that predict lung function and quality of life decline in a COPD cohort, …

… to predict responses to inhaled corticosteroids (ICS) in COPD … long-acting bronchodilators
with or without ICS has involved some landmark randomized controlled trials in COPD patients…

… predicted FEV1 in COPD patients … long-acting bronchodilators in patients with stable COPD,
so the effects of exacerbation of COPD, short-acting bronchodilators, or short-term treatment …

… Baseline characteristics were assessed in the baseline period before the index … -bronchodilator
forced expiratory volume in 1 second [FEV 1 ] and pre-bronchodilator FEV 1 % predicted) …

… This post hoc analysis of the “Early MAXimization of bronchodilation for improving COPD
stability” (EMAX) trial investigated whether patients achieving early clinically important …

… with severe airway obstruction with a mean FEV 1 of 21.1 ± 5.6% predicted (… patients were
under treatment with systemic corticosteroids on top of dual or triple inhaled bronchodilator …